Company: MDCXW
Filing Date: 2025-11-17
Form Type: 424B3
Source: 0001062993-25-016880
Chunk: 18

Company: Medicus Pharma Ltd.
Filing Date: 2025-11-17
Form: 424B3
Chunk 18
---
2,443,344 |
| Cash paid                                              |   | 2,970,166 |
| Transaction expenses                                   |   | 1,992,798 |
| Contingent consideration                               |   |       Nil |
| Total fair value consideration                         |   | 7,406,308 |
| Fair value of non-controlling interest                 |   |   105,161 |
| Total fair value for allocation to net assets of Antev |   | 7,511,469 |

Due to the nature of the regulatory, sales and financing-based milestones, the contingent consideration was not included in the initial cost of assets acquired as they are contingent upon events that are outside the Company's control. Contingent consideration will recognized when it becomes probable that the milestone conditions will be met and the amount can be estimated. As of September 30, 2025, none of the contingent events had occurred, nor were the milestone conditions considered probable to be met. The allocation of Antev's net assets acquired was as follows:

| Cash                               | $ |     13,353 |   |
| Assets                             |   |    224,719 |   |
| Accrued and other accounts payable |   | (1,327,429 | ) |
| Other liabilities                  |   |   (116,649 | ) |
| IPR&D - Teverelix                  |   |  8,717,475 |   |
| Net assets acquired                | $ |  7,511,469 |   |

All costs allocated to IPR&D by the Company were recognized as research and development expenses in the Company's condensed consolidated statement of operations and comprehensive loss as these assets had no alternative future use at the time of the acquisition transaction.

19 13. Liquidity The Company expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays or entirely prevent the Company's continued efforts to commercialize its current or future products, which are critical to the realization of its business plan and the future operations of the Company. This uncertainty, along with the Company's history of losses, indicates that there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying condensed consolidated financial statements do not